A review of 37 studies found that when people stop taking weight-loss drugs like Ozempic, the weight comes back. Experts ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with ...

Researchers have quantified the role of obesity in common long-term conditions, showing for the first time the effect of ...

Researchers are applying insights into the genetic variations and physiology of obesity to apply tailored interventions to ...

Over the next decade, obesity rates across the nation could surge to close to half of U.S. adults, a new study published in ...

Researchers reviewed the body mass index of over 11 million Americans.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Obesity is contributing to a record proportion of deaths among pregnant women, the Royal College of Physicians has warned.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...